Alzheimer’s and other neurodegenerative diseases are not one pathology or disease, but rather comprise many subgroups and sub-pathologies.
Just like one drug cannot treat every cancer patient, one drug or treatment plan cannot treat every patient afflicted with Alzheimer’s Disease, or any neurodegenerative disease, for that matter.
Our technology is based on a series of blood-based biomarkers related to Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions. The biomarkers, discovered after analyzing thousands of patient blood samples, are used in rule-out tests for rapid, early diagnosis of people with memory loss concerns. The diagnostics also can be applied for matching therapeutics to neurodegenerative disease patients.
The rule-out tests measure blood levels of a specific set of biomarkers. A computer algorithm then determines if the levels of each biomarker, considered in combination, indicate a disease, such as Alzheimer’s, is not present, or if further testing is indicated. The tests are similar to others that rule out the presence of disease, such as mammography for breast cancer and the PSA (prostate specific antigen) blood test for prostate cancer.
Cx Precision Medicine technology enables physicians at the primary care level to more accurately diagnose neurodegenerative disorders leading to earlier, targeted treatments for individual patients.
Simple and rapid rule-out tests are highly accurate in screening out those who do not have a disease. Those who are not ruled out can then be recommended for further diagnostic testing.
CxPM Rule-Out Tests in our pipeline include tests for Alzheimer’s disease, Parkinson’s disease and Lewy body dementia.
Blood-based biomarkers can predict whether certain drugs are likely to be effective in treating Alzheimer’s disease and Parkinson’s disease. This information can provide physicians with guidance for drug prescribing and also identify potential clinical trial participants who would benefit from new therapies.
